Key facts
- Rila Therapeutics’s last known valuation is $60.0M (Jan 2025).
- It has raised $7.0M across 1 recorded rounds; the latest was Early Stage VC ($7.0M) in Dec 2024.
- Notable investors include ShangPharma Innovation, Shafa Invest.
- Rila Therapeutics has filed 1 Form D with the SEC, most recently Jan 2025 ($7.0M sold to 3 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Rila Therapeutics
Funding rounds
1 roundsAbout Rila Therapeutics
Operator of a biotherapeutics company intended to address the burden of chronic fibrotic diseases. The company focuses on addressing the critical medical needs to treat renal fibrosis, and its program is a first-in-class small molecule allosteric inhibitor targeting kidney fibrosis, enabling the medical industry to improve the lives of patients suffering from renal fibrosis by providing a safe and effective anti-fibrotic therapy.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2021
- Employees
- 2
- Website
- rilatx.com/
- Ownership
- Privately Held (backing)
Rila Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rila Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rila Therapeutics in its N-PORT filings yet. We sweep new filings monthly.